Delving into the Latest Updates on 20-valent Pneumococcal Conjugate Vaccine(Pfizer) with Synapse

Overview

Basic Info

Drug Type

Inactivated vaccine, Prophylactic vaccine, Multivalent vaccine

+ [1]

Synonyms

Multivalent Pneumococcal conjugate vaccine, Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal conjugate vaccine

+ [13]

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesOtorhinolaryngologic DiseasesRespiratory Diseases

Active Indication

invasive Streptococcus pneumoniae infectionOtitis MediaPneumococcal Infections+ [5]

Inactive Indication

COVID-19Influenza, Human

Originator Organization

Wyeth Pharmaceuticals LLC

Active Organization

Pfizer Japan, Inc.Pfizer Europe MA EEIG

Pfizer Inc.

+ [4]

Inactive Organization-

License Organization

Pfizer Pharmaceuticals Korea Ltd.

Korea Vaccine Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

United States (08 Jun 2021),

Invasive streptococcal disease

RegulationBreakthrough Therapy (United States), Fast Track (United States), Priority Review (United States)

Login to view timeline

Structure/Sequence

Sequence Code 1148399

The purpose of this study is to understand the safety of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine) once it is out in the Korean market. Prevenar 20 will be given to participants aged 6 weeks or older in Republic of Korea.
This study is seeking for participants who are:
* Infant, children and adolescents aged 6 weeks to under 18 years or adult who are 18 years or older
* Prescribed Prevenar 20 by their physician as per approved product label
All participants in this study will receive Prevenar 20 vaccine.
1 dose (0.5 mL) of Prevenar 20 will be given into a muscle, preferably to the shoulder muscle.
We will look at the experiences of people receiving the study medicine. This will help us see if the study medicine is safe.
Participants will take part in this study for 28 days. During this time, study doctor collects the data of subjects to understand the safety of study medicine. There is no strict fixed visit schedule. If subjects are unable to visit the study clinic 28 days after Prevenar 20 vaccine was given then the safety information will be collected by telephone or e-mail.

Start Date01 Sep 2025

Sponsor / Collaborator

Pfizer Inc.

NCT06855160

/ Not yet recruitingPhase 3

A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and Priorix Compared With Subcutaneous Administration of Varivax and Priorix, When Given as a First Dose to Healthy Children 12 to 15 Months of Age

This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Additionally, the study will evaluate the immune response and safety of giving the GSK vaccines along with other childhood vaccines through a muscle injection.

Start Date21 Apr 2025

Sponsor / Collaborator

GSK Plc

NCT06806137

/ Not yet recruitingPhase 3

A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, When Given as a Second Dose to Healthy Children, 3 Months After the Administration of a First Dose at 12 to 15 Months of Age

The purpose of this study is to evaluate the immune response and safety of GSKs investigational varicella vaccine (VNS Vaccine) compared to an already approved varicella vaccine, Varivax (VV), when administered as second dose to healthy children. 3 months after first dose at 12 to 15 months. The study will be conducted in children who have not previously contracted varicella or received a varicella vaccination.

Start Date05 Mar 2025

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

Login to view more data

100 Translational Medicine associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

Login to view more data

100 Patents (Medical) associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

Login to view more data

2,254

Literatures (Medical) associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

31 Dec 2025·Human Vaccines & Immunotherapeutics

PCV20 for the prevention of invasive pneumococcal disease in the Mexican pediatric population: A cost-effectiveness analysis

Article

Author: Vinand, Elizabeth ; Torres, Gustavo Ivan ; Huang, Liping ; Ta, An ; Wannaadisai, Warisa ; Huerta, José Luis

The introduction of a pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) into the Mexican pediatric national immunization program (NIP) has substantially reduced the burden of pneumococcal disease (PD) since 2010. This study aimed to estimate the impact of replacing either PCV13 or 15valent PCV (PCV15) with 20-valent PCV (PCV20) in the Mexican pediatric NIP. A decision-analytic Markov model was developed to compare the cost-effectiveness of PCV20 versus lower-valent vaccines from a Mexican public health sector (payer) perspective over 10 years. Epidemiological and cost inputs were sourced from Mexican data. Direct and indirect vaccine effects were estimated using PCV13 clinical effectiveness, 7-valent PCV efficacy studies, and PCV13 impact data in Mexico. The estimated disease and cost impact of PCV20 was compared with PCV13 and PCV15, all under a 2 + 1 dosing schedule. A discount rate of 5% per annum was applied to costs and health outcomes. Model robustness was evaluated through sensitivity analyses, including deterministic sensitivity analysis (DSA), probabilistic sensitivity analysis (PSA), and additional scenario assessments. PCV20 was estimated to provide considerably more health benefits than both comparators by averting more cases of PD compared with both PCV13 and PCV15, as well as a total cost saving of over 10 billion Mexican pesos. The DSA, PSA, and scenario assessments confirmed minimal deviation from the base case. Therefore, the introduction of PCV20 (2 + 1) into the Mexican pediatric NIP is expected to reduce the burden of PD and medical costs compared with lower-valent alternatives.

31 Dec 2025·Human Vaccines & Immunotherapeutics

Pneumococcal vaccine hyporesponsiveness in people living with HIV: A narrative review of immunological mechanisms and insights from minimally invasive lymph node sampling

Review

Author: de Vos, Danny W. ; Visser, Leo G. ; Jochems, Simon P. ; Loe-Sack-Sioe, Giovanni E. ; Roukens, Anna H. E.

Despite highly effective antiretroviral therapy, people living with HIV (PLWH) remain at elevated risk for invasive pneumococcal disease. Clinical studies show that, even with high CD4⁺ counts, PLWH exhibit diminished serological responses and rapid antibody decline following pneumococcal vaccination, plausibly due to underlying immune dysfunction. Germinal centers (GCs), located within lymph nodes, are essential for generating high-affinity antibodies, but are structurally and functionally disrupted in PLWH. These local impairments, combined with systemic immune dysregulation, contribute to vaccine hyporesponsiveness in PLWH. This narrative review links immunological findings from experimental and in vivo studies to clinical pneumococcal vaccine trials, to investigate mechanisms that may be leveraged to strengthen vaccine-induced immunity in PLWH. We also highlight the application of fine needle aspiration (FNA) of the lymph node as a way to study pneumococcal vaccine hyporesponsiveness in the GC and provide potential direction to improve responses for next-generation pneumococcal conjugate vaccines in PLWH.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) for adults in Japan: a delta price approach

Article

Author: Cassell, Kelsie ; Owusu-Edusei, Kwame ; Mueller, Peter P. ; Johnson, Kelly D. ; Tajima, Atsushi ; Cossrow, Nicole ; Yi, Zinan ; Matsuki, Taizo

INTRODUCTION:

This study analyzed the health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) and the 20-valent pneumococcal conjugate vaccine (PCV20), as well as their relative cost-effectiveness, in Japanese adults aged 65 years using a delta pricing approach.

METHODS:

A Markov model was employed to simulate the movement of the Japanese population among four health states: healthy, pneumococcal disease (consisting of invasive pneumococcal disease [IPD] with or without meningitis and non-bacteremic pneumococcal pneumonia [NBPP]), post-meningitis sequelae, and death. The model was populated with publicly available demographic and epidemiologic data, stratified by risk level. Pneumococcal serotype distribution and vaccine effectiveness, as well as direct and indirect treatment costs and health-related utilities, were derived from published sources. The model used a lifetime horizon and 2% discounting of costs and life-years. Costs were adjusted to 2023 values in Japanese yen (¥). Outcomes were cases and deaths, life-years and quality-adjusted life-years (QALYs), vaccination and treatment costs, and incremental cost-effectiveness ratios. The range over which V116 was cost-saving and cost-effective was determined.

RESULTS:

Compared to PCV20, V116 averted an additional 28 cases of IPD, 918 cases of NBPP, 5 deaths from IPD, and 51 deaths from NBPP over the lifetime of a single age 65 cohort. Life-years and QALYs gained were 1,019 and 642, respectively, relative to PCV20; V116 saved ¥733 million in direct medical costs and ¥557 million in indirect costs, compared to PCV20. V116 was found to be cost-saving at price premiums up to ¥1,322 (payer perspective) or ¥2,327 (societal perspective) and remained below a willingness-to-pay threshold of ¥5 million/QALY for premiums up to ¥7,113 (payer perspective) or ¥8,117 (societal perspective).

CONCLUSIONS:

V116 is projected to provide more population health benefits in Japan than PCV20, and to be cost-effective at a variety of price premiums.

109

News (Medical) associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

21 May 2025

·www.prnewswire.com

SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 to Russia Company plans to export PCV13 vaccine components "We aim for the global PCV market with our 21-valent and next-generation pneumococcal vaccines currently under development." SEONGNAM, South Korea, May 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it the Supreme Court of Korea has ruled in its favor in a patent infringement lawsuit filed by large global pharmaceutical giant Pfizer over its 13-valent pneumococcal conjugate vaccine (PCV13). In 2020, Pfizer claimed that SK bioscience's export of PCV13 individual conjugate bulk substances and research-use finished products to Russia infringed on the composition patent of its vaccine, Prevnar 13. Continue Reading SK bioscience L HOUSE manufacturing plant However, the Supreme Court ruled that the individual conjugates comprising PCV13 do not fall within the scope of Pfizer's patent claims, thereby upholding the lower court's ruling in favor of SK bioscience. The Court also confirmed that the production and supply of PCV13 finished products for research purposes did not constitute patent infringement. SK bioscience successfully developed Korea's first 13-valent pneumococcal conjugate vaccine, SKYPneumo, in 2016. However, due to the ongoing patent dispute with Pfizer, the company has been prohibited from manufacturing and selling the vaccine in Korea until 2027, when the related patents set to expire. Following the ruling, SK bioscience now plans to initiate new business in pneumococcal conjugate vaccines by exporting individual components of PCV13 to countries with high vaccine demand, such as those in Southeast Asia and Latin America. Technology transfers through local partnerships are also being pursued in parallel. Looking ahead, SK bioscience aims to expand its presence in the global pneumococcal vaccine market. From 2027, the company will be able to manufacture and sell SKYPneumo domestically. In addition, the company is developing a 21-valent pneumococcal conjugate vaccine with global pharmaceutical company Sanofi, which entered Phase 3 global clinical in late 2024. Simultaneously, the two companies are also working on a next-generation pneumococcal vaccine that is expected to offer broader protection than current options. The global pneumococcal vaccine market continues to grow. According to Global Market Insights, the market is projected to grow at a compound annual rate of approximately 5.6% to reach USD 15.1 billion (approximately KRW 21.55 trillion) by 2034. This growth is driven by expanded vaccination programs and support from governments and international organizations like WHO and Gavi. SK bioscience's strong track record in public vaccine supply and cooperation with global health organizations positions it well for future expansion. Jaeyong Ahn, CEO of SK bioscience, said, "This latest court decision is meaningful in that it ensures a competitively developed vaccine in Korea does not go to waste but instead finds new opportunity. We will leverage this momentum to improve access to premium vaccines, contribute to a stable global vaccine supply, and achieve sustainable growth." Meanwhile, SK bioscience recently secured a definitive legal victory in a patent invalidation suit against Moderna, successfully challenging the biotech giant's Korean patent related to messenger RNA (mRNA) vaccine technology. The contested patent covers 'modified nucleosides, nucleotides, and nucleic acids and their uses.' This case, which invalidated the only registered mRNA manufacturing patent in Korea, regarded as a major step in reducing patent-related risks and removing barriers to innovation for domestic companies engaged in mRNA research and development. About SK bioscience SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions. - SK bioscience Website - SK bioscience Linkedin Contact SK bioscience Communications Team Changhyun Jin ([email protected]) Jeannie S. Pak ([email protected]) SOURCE SK bioscience WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VaccinePatent InfringementmRNAPhase 3

19 May 2025

·pmlive.com

Merck receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive

Merck & Co – known as MSD outside the US and Canada – has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its adult-specific pneumococcal vaccine Capvaxive. The vaccine has been authorised to help protect adults aged 18 years and older against illnesses caused by Streptococcus pneumoniae bacteria, including pneumonia and meningitis, which are currently considered a “major public health problem” by the World Health Organization (WHO). There are over 100 different types of pneumococcal bacteria and Merck’s Capvaxive, a single-dose 21-valent-vaccine, is specifically designed to help protect against the ones that are responsible for the majority of adult invasive pneumococcal disease. The MHRA’s decision on Capvaxive occurred through the International Recognition Procedure, a fast-track approval process that takes into account prior authorisations from other regulatory partners, and follows the European Commission’s approval of the vaccine in March. Among the evidence supporting the EU regulator’s decision were results from a phase 3 trial comparing Capvaxive to Pfizer’s 20-valent vaccine (PCV20) in adults who had not previously received a pneumococcal vaccine. Capvaxive was shown to induce non-inferior immune responses compared to PCV20 for all ten serotypes common to both vaccines in adults aged 50 years and older, and generated superior immune responses for ten of its 11 unique serotypes. Merck’s vaccine was also shown to elicit non-inferior immune responses in adults aged 18 to 49 years compared to those aged 50 to 64 years and had a safety profile comparable to PCV20. “As with any medicine, the MHRA will keep the safety and effectiveness of this vaccine under close review,” the UK regulator said. Emma Cerrone, vaccines business unit director, MSD UK, said: “We are delighted with this decision. Pneumococcal infections can lead to serious complications requiring hospital treatment, however immunisation plays a vital role in prevention and can help adults live longer, healthier lives.” Alongside the EU, Capvaxive is approved in the US, Canada and Australia.

Drug ApprovalClinical ResultPhase 3Vaccine

28 Mar 2025

·pmlive.com

Merck granted EC approval for adult-specific pneumococcal vaccine Capvaxive

Merck & Co – known as MSD outside the US and Canada – has announced that its adult-specific 21-valent pneumococcal conjugate vaccine has been approved by the European Commission (EC). The vaccine, marketed under the brand name Capvaxive, has been authorised to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals aged 18 years and older. Invasive pneumococcal disease, including pneumonia, sepsis and meningitis, are major causes of mortality worldwide. There are more than 100 different types of pneumococcal bacteria and Merck’s Capvaxive, which is administered in a single dose, is designed to help protect against the ones that are responsible for the majority of adult invasive pneumococcal disease. The EC’s approval follows a recent recommendation from the European Medicines Agency’s human medicines committee and was based on positive results from the phase 3 STRIDE-3 trial, which compared Capvaxive to Pfizer’s 20-valent vaccine (PCV20) in adults who had not previously received a pneumococcal vaccine. Capvaxive was shown to induce non-inferior immune responses compared to PCV20 for all ten serotypes common to both vaccines in adults aged 50 years and older, and generated superior immune responses for ten of its 11 unique serotypes. Additionally, Merck’s vaccine elicited non-inferior immune responses in adults aged 18 to 49 years compared to those aged 50 to 64 years and had a safety profile comparable to PCV20. Results from the phase 3 STRIDE-4, STRIDE-5, STRIDE-6, STRIDE-7 and STRIDE-10 trials also supported the EU regulator’s decision. Paula Annunziato, senior vice president, infectious diseases and vaccines, global clinical development at Merck Research Laboratories, said: “By focusing on the serotypes that have been responsible for an increasing proportion of adult invasive pneumococcal disease cases, Capvaxive allows us to offer protection specifically designed for adults. “We are proud to bring Capvaxive to adults in Europe who may benefit from its broad protection and are eager to continue working with regulatory authorities to expand Capvaxive availability worldwide.” The authorisation follows the US Food and Drug Administration’s approval of Capvaxive in June last year. The vaccine is also already approved in Canada and Australia.

Drug ApprovalPhase 3Clinical ResultVaccine

100 Deals associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07AL	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
invasive Streptococcus pneumoniae infection	South Korea	Pfizer Pharmaceuticals Korea Ltd.	31 Oct 2024
Otitis Media	United States	Wyeth Pharmaceuticals LLC	27 Apr 2023
Pneumococcal Infections	Canada	Pfizer Canada ULC	09 May 2022
Pneumonia, Pneumococcal	European Union	Pfizer Europe MA EEIG	14 Feb 2022
Pneumonia, Pneumococcal	Iceland	Pfizer Europe MA EEIG	14 Feb 2022
Pneumonia, Pneumococcal	Liechtenstein	Pfizer Europe MA EEIG	14 Feb 2022
Pneumonia, Pneumococcal	Norway	Pfizer Europe MA EEIG	14 Feb 2022
Invasive streptococcal disease	United States	Wyeth Pharmaceuticals LLC	08 Jun 2021

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute otitis media	NDA/BLA	European Union	Pfizer Europe MA EEIG	26 Jan 2024
Respiratory Syncytial Virus Infections	NDA/BLA	United States	Pfizer Inc.	17 May 2023
COVID-19	Phase 3	United States	Pfizer Inc.	20 May 2021
Influenza, Human	Phase 3	United States	Pfizer Inc.	01 Sep 2020
Infectious Lung Disorder	Phase 2	United States	Pfizer Inc.	05 Jun 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05879107 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections	1,113	PCV20+RSVPreF3 OA investigational vaccine (Co-administration Group)	odplojdair(dlanymdgdi) = dwsxgonmgv tvpedhvfhv (xeleydlusp, ygnokrekik - vgfhrfbcsd) View more	-	18 May 2025
				PCV20+RSVPreF3 OA investigational vaccine (Control Group)	odplojdair(dlanymdgdi) = hkjjfzaxye tvpedhvfhv (xeleydlusp, vnjwmqmmfh - eihyjzgloa) View more
NCT05886777 (CTgov)	Phase 2	COVID-19 \| Infectious Lung Disorder	1,142	QIV+RSVpreF (Group 1: [RSVpreF + BNT162b2] + QIV)	jwzvbkdlzx = kqabxjpuwu rmodehdcyg (driasosmjg, ogdeyablpb - hlevgucfef) View more	-	18 Dec 2024
				Placebo+BNT162b2+RSVpreF (Group 2: [RSVpreF+BNT162b2] + Placebo)	jwzvbkdlzx = pnjdgncecy rmodehdcyg (driasosmjg, zyewzigxfg - yuflofbump) View more
NCT05875727 (CTgov)	Phase 3	Pneumococcal Infections	405	Pneumococcal vaccine (Cohort 1: 18 to 49 Years)	dlekwgdgel = tlirpwuvue uvesdzkplo (vhflzobsew, fjjfgoavss - qjfzuigwer) View more	-	24 Oct 2024
				Pneumococcal vaccine (Cohort 2: >= 50 Years)	dlekwgdgel = lbaygzvxpp uvesdzkplo (vhflzobsew, qmptbbbotl - fkgrccgkwt) View more
NCT05408429 (CTgov)	Phase 3	Pneumococcal Infections	356	20vPnC (2-Dose 20vPnC)	ktgbdzpyiy = gyjtatlrjo yudyuwkrzq (qnkmabsimq, ufuhxqmkoo - iojukkwmkc) View more	-	19 Sep 2024
				20vPnC (1-Dose 20vPnC)	ktgbdzpyiy = zchlikqssg yudyuwkrzq (qnkmabsimq, osbdsywlib - yjshqpexrz) View more
NCT04382326 (CTgov)	Phase 3	Pneumococcal Infections	1,997	20-valent Pneumococcal Conjugate Vaccine (20vPnC) (20vPnC)	euiairjmja = nuhpmzrgnu rmyhgrocpu (fyfssvxckq, ytrvxcigkt - uclmiqigbd) View more	-	06 Dec 2023
				13-valent Pneumococcal Conjugate Vaccine (13vPnC) (13vPnC)	euiairjmja = kwmnogafsc rmyhgrocpu (fyfssvxckq, dysdqpiyra - gzetidkgrs) View more
NCT04379713 (CTgov)	Phase 3	Pneumococcal Infections	1,511	20vPnC (20vPnC)	dfdgeaxlpi = whgfdqsalc avijukdiwn (evweiujpuf, rcmicdybcd - jcmfqznfrg) View more	-	13 Jun 2023
				13vPnC (13vPnC)	dfdgeaxlpi = tktblepqsp avijukdiwn (evweiujpuf, jzhcxocuho - ttnxhotmpg) View more
NCT04642079 (CTgov)	Phase 3	Pneumococcal Infections	839	20vPnC+13vPnC (Cohort 1: 20vPnC: >=15 to <24 Months)	uvwisetilh = ayiklvqjqz olzxwfztsx (qqtydjisoz, tktacqtpjt - erjfvdytsl) View more	-	26 Apr 2023
				20vPnC+13vPnC (Cohort 2: 20vPnC: >=2 to <5 Years)	uvwisetilh = bifvdjjgej olzxwfztsx (qqtydjisoz, ovjcbqcwpm - gkfsmqlhhl) View more
NCT04530838 (CTgov)	Phase 3	Pneumococcal Infections	668	20vPnC (20vPnC (SC))	boblkfpjti = acirvwjaux aniacqxhhx (aunjczerrh, imzepvyozh - oaymdfjjcj) View more	-	21 Apr 2023
				13vPnC (13vPnC (SC))	boblkfpjti = qclahgnxah aniacqxhhx (aunjczerrh, ecrlelpavx - eowugvdalw) View more
NCT04887948 (CTgov)	Phase 3	COVID-19 \| Pneumococcal Infections	570	BNT162b2+20vPnC (Coadministration Group (20vPnC+BNT162b2): 20vPnC Vaccination Site)	unqqseushz = ahaezgfthe uwfbgyashd (xtdsjkjdfm, rplyazhxlp - vntxspcfqa) View more	-	14 Dec 2022
				BNT162b2+20vPnC (Coadministration Group (20vPnC+BNT162b2): BNT162b2 Vaccination Site)	unqqseushz = oxjmdbtqob uwfbgyashd (xtdsjkjdfm, vutdavvrvo - kewmkdwrms) View more
NCT04546425 (Corporate Publications) Manual	Phase 3	Pneumococcal Infections	-	20-Valent Pneumococcal Conjugate Vaccine	pcsqiywrnc(ywsghwnhqj) = The safety profile of 20vPnC was favorable and similar to Prevenar 13® (or Prevnar 13® in the U.S.) in this schedule, and concomitant use with common pediatric vaccines was supported and well tolerated wfftbqjzyn (sribkajaxu )	Non-inferior	19 Sep 2022
				Prevenar 13